Banner

Hepatitis Drugs Global Market Report 2023 – By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents), By Route Of Administration (Oral, Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 200 | Published : January 2023 | SKU CODE : h2383 | Delivery Time: 2-3 business days | Format :


Hepatitis drugs refer to a medication that aggravates liver inflammation. A number of viruses (viral hepatitis), substances, medications, alcohol, certain genetic abnormalities, an overactive immune system that mistakenly assaults the liver (autoimmune hepatitis), and other factors, can result in liver inflammation.

The main type of hepatitis drugs interferon alphas, HIV NRTIS, nucleotide polymerase / NS5A inhibitor combinations, hepatitis C protease / NS5A inhibitor combinations, NS5A inhibitors, nucleotide polymerase inhibitors, nucleoside analog antivirals, and thrombopoiesis stimulating agents. The interferon alphas are the innate immune system in response to environmental exposures such as viral infections. Interferon alpha has been developed in different formulations for the treatment but mainly for chronic hepatitis C. The drugs are consumed through oral or injection route of administration and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. These drugs are used to treat hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E.

The hepatitis drugs market research report is one of a series of new reports from The Business Research Company that provides hepatitis drugs market statistics, including hepatitis drugs industry global market size, regional shares, competitors with an hepatitis drugs market share, detailed hepatitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis drugs industry. This hepatitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global hepatitis drugs market size grew from $18.63 billion in 2022 to $19.38 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hepatitis drugs market size is expected to grow to $23.69 billion in 2027 at a CAGR of 5.2%.

The increase in number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drug market. Various types of hepatitis need different drugs for treatment, which increases the demand for hepatitis drugs. For instance, in June 2022, according to the World Health Organization (WHO), a Switzerland based international public health organization, 296 million people had a chronic hepatitis B infection, with an average of 1.5 million new infections every year. This increasing number of hepatitis infections will invariably increase the need for and consumption of hepatitis drugs. Thus, the increasing number of different types of hepatitis is expected to propel the growth of hepatitis drugs in the forecast period.

New product launches are a significant trend in the hepatitis drugs market. The key players in the hepatitis drugs sector are focusing on launching new products for hepatitis treatments to strengthen their position in the market. For instance, in September 2020, MYR Pharmaceuticals, a Germany-based biotechnology company, launched HEPCLUDEX (bulevirtide) in Germany, France, and Austria for the treatment of chronic hepatitis B and D. HEPCLUDEX® is the first European drug to be approved for the treatment of chronic hepatitis D. HEPCLUDEX® inhibits the entry of HBV/HDV into hepatocytes and viral spread within the liver by blocking the NTCP receptor on the surface of hepatocytes.

In March 2021, Gilead Sciences, a US-based biopharmaceutical company acquired MYR GmbH for cash consideration of $1.55 billion (€1.45 billion). As a result of the acquisition, Gilead leverages the MYR GmbH’s new drugs and expansion of the market globally in providing better treatment for hepatitis. MYR GmbH is a Germany-based company that develops inhibitors for chronic hepatitis B and D infections.

Major players in the hepatitis drugs market are Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, and Dynavax Technologies Corporation.

North America was the largest region in the hepatitis drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the hepatitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The hepatitis drugs market consists of sales of ribavirin, elbasvir-grazoprevir, and glecaprevir-pibrentasvir. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global hepatitis drugs market is segmented -

1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents 

2) By Route Of Administration: Oral, Injection

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E

    Table Of Contents

    1. Executive Summary

    2. Hepatitis Drugs Market Characteristics

    3. Hepatitis Drugs Market Trends And Strategies

    4. Hepatitis Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Hepatitis Drugs Market

    4.2 Ukraine-Russia War Impact On Hepatitis Drugs Market

    4.3 Impact Of High Inflation On Hepatitis Drugs Market

    5. Hepatitis Drugs Market Size And Growth

    5.1. Global Hepatitis Drugs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Hepatitis Drugs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Hepatitis Drugs Market Segmentation

    6.1. Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Interferon Alphas

    HIV NRTIs

    Nucleotide Polymerase / NS5A Inhibitor Combinations

    Hepatitis C Protease / NS5A Inhibitor Combinations

    NS5A Inhibitors

    Nucleotide Polymerase Inhibitors

    Nucleoside Analogue Antivirals

    Thrombopoiesis Stimulating Agents

    6.2. Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oral

    Injection

    6.3. Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    6.4. Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hepatitis A

    Hepatitis B

    Hepatitis C

    Hepatitis D

    Hepatitis E

    7. Hepatitis Drugs Market Regional And Country Analysis

    7.1. Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Hepatitis Drugs Market

    8.1. Asia-Pacific Hepatitis Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Hepatitis Drugs Market

    9.1. China Hepatitis Drugs Market Overview

    9.2. China Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Hepatitis Drugs Market

    10.1. India Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Hepatitis Drugs Market

    11.1. Japan Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Hepatitis Drugs Market

    12.1. Australia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Hepatitis Drugs Market

    13.1. Indonesia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Hepatitis Drugs Market

    14.1. South Korea Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Hepatitis Drugs Market

    15.1. Western Europe Hepatitis Drugs Market Overview

    15.2. Western Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Hepatitis Drugs Market

    16.1. UK Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Hepatitis Drugs Market

    17.1. Germany Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Hepatitis Drugs Market

    18.4. France Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Hepatitis Drugs Market

    19.1. Eastern Europe Hepatitis Drugs Market Overview

    19.2. Eastern Europe Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Hepatitis Drugs Market

    20.1. Russia Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Hepatitis Drugs Market

    21.1. North America Hepatitis Drugs Market Overview

    21.2. North America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Hepatitis Drugs Market

    22.1. USA Hepatitis Drugs Market Overview

    22.2. USA Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Hepatitis Drugs Market

    23.1. South America Hepatitis Drugs Market Overview

    23.2. South America Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Hepatitis Drugs Market

    24.1. Brazil Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Hepatitis Drugs Market

    25.1. Middle East Hepatitis Drugs Market Overview

    25.2. Middle East Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Hepatitis Drugs Market

    26.1. Africa Hepatitis Drugs Market Overview

    26.2. Africa Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Hepatitis Drugs Market Competitive Landscape And Company Profiles

    27.1. Hepatitis Drugs Market Competitive Landscape

    27.2. Hepatitis Drugs Market Company Profiles

    27.2.1. Gilead Sciences Inc

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. F Hoffmann-La Roche Ltd

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Johnson & Johnson

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Merck & Co Inc

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. GlaxoSmithKline PLC

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Hepatitis Drugs Market

    29. Hepatitis Drugs Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Historic And Forecast Inflation Rates

    30.4. Research Inquiries

    30.5. The Business Research Company

    30.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: China, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: India, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Japan, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Australia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Indonesia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: South Korea, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Western Europe, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: UK, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: Germany, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: France, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Eastern Europe, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: Russia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: North America, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: USA, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: South America, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Brazil, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Middle East, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Africa, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: Gilead Sciences Inc Financial Performance
  • Table 48: F Hoffmann-La Roche Ltd Financial Performance
  • Table 49: Johnson & Johnson Financial Performance
  • Table 50: Merck & Co Inc Financial Performance
  • Table 51: GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Hepatitis Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Hepatitis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Hepatitis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Global Hepatitis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: China, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: India, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Japan, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Australia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Indonesia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: South Korea, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Western Europe, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: UK, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: Germany, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: France, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Eastern Europe, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: Russia, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: North America, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: USA, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: South America, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Brazil, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Middle East, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Hepatitis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Africa, Hepatitis Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: Gilead Sciences Inc Financial Performance
  • Figure 48: F Hoffmann-La Roche Ltd Financial Performance
  • Figure 49: Johnson & Johnson Financial Performance
  • Figure 50: Merck & Co Inc Financial Performance
  • Figure 51: GlaxoSmithKline PLC Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report